Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor

Blood

Volumn 125, Issue 4, 2015, Pages 710-719

  Stavrou, Evi X ^a,b   Fang, Chao ^a   Merkulova, Alona ^a   Alhalabi, Omar ^a   Grobe, Nadja ^c   Antoniak, Silvio ^d   Mackman, Nigel ^d   Schmaier, Alvin H ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BRADYKININ; HYDROLASE INHIBITOR; KRUPPEL LIKE FACTOR 4; MAS RECEPTOR; MESSENGER RNA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NIMESULIDE; PROSTACYCLIN; RECEPTOR; SIRTUIN 1; SPLITOMICIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; 7-ALA-ANGIOTENSIN (1-7); ANGIOTENSIN II; BRADYKININ B2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; KRUPPEL LIKE FACTOR; NAPHTHALENE DERIVATIVE; NERVE PROTEIN; ONCOPROTEIN; PEPTIDE FRAGMENT; PREKALLIKREIN; PROTO-ONCOGENE PROTEINS C-MAS-1; PYRONE DERIVATIVE; SIRT1 PROTEIN, MOUSE; SULFONAMIDE; SYNAPTOTAGMIN; SYT17 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; KLKB1 MOUSE; KNOCKOUT MOUSE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CAROTID ARTERY THROMBOSIS; CHEMICALLY INDUCED; GENETICS; METABOLISM; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY;

ANGIOTENSIN II; ANIMALS; CAROTID ARTERY THROMBOSIS; EPOPROSTENOL; IMIDAZOLES; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, KNOCKOUT; NAPHTHALENES; NERVE TISSUE PROTEINS; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PREKALLIKREIN; PROTO-ONCOGENE PROTEINS; PYRONES; RECEPTOR, BRADYKININ B2; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; SIRTUIN 1; SULFONAMIDES; SYNAPTOTAGMINS; THROMBOPLASTIN;

EID: 84921467982     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-550285     Document Type: Article

References (46)

1. Scott CF, Colman RW. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest. 1980;65(2):413-421.
2. nd ed. Philadelphia, PA: Lippincott; 1987:18-36.
3. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med. 1978; 147(3):719-729.
4. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002;277(20): 17962-17969.
5. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145(3638): 1310-1312.
6. Colman RW, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. 1969;48(1):11-22.
7. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Røjkjaer R, Schmaier AH. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol. 2001;280(4): H1821-H1829.
8. Zini JM, Schmaier AH, Cines DB. Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood. 1993;81(11): 2936-2946.
9. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526.
10. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res. 1980;18(6):787-795.
11. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66(4):835-839.
12. Hasan AA, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation. 1996;94(3): 517-528.
13. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109(8):1057-1063.
14. Abildgaard CF, Harrison J. Fletcher factor deficiency: family study and detection. Blood. 1974;43(5):641-644.
15. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19): 5302-5311.
16. Bird JE, Smith PL, Wang X, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost. 2012;107(6): 1141-1150.
17. Shariat-Madar Z, Mahdi F, Warnock M, et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood. 2006;108(1): 192-199.
18. Fang C, Stavrou E, Schmaier AA, et al. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood. 2013;121(15):3023-3032.
19. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011;17(2):206-210.
20. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost. 2006;95(6):1003-1010.
21. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
22. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6): 1143-1156.
23. Matute-Bello G, Downey G, Moore BB, et al Acute Lung Injury in Animals Study Group. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725-738.
24. Schmaier AH. The kallikrein-kinin and the reninangiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol. 2003;285(1):R1-R13.
25. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281.
26. Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M, Santos RA. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2008;14(1-2):28-35.
27. Fraga-Silva RA, Sorg BS, Wankhede M, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010;16(5-6):210-215.
28. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension. 2002;40(5):774-779.
29. Ghosh M, Wang H, Ai Y, et al. COX-2 suppresses tissue factor expression via endocannabinoiddirected PPARdelta activation. J Exp Med. 2007; 204(9):2053-2061.
30. Breitenstein A, Stein S, Holy EW, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res. 2011;89(2):464-472.
31. Barbieri SS, Amadio P, Gianellini S, et al. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation. 2012;126(11):1373-1384.
32. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation. 2010;121(13):1510-1517.
33. Bhattacharjee G, Revenko AS, Crosby JR, et al. Inhibition of vascular permeability by antisensemediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013; 23(3):175-187.
34. Björkqvist J, Sala-Cunill A, Renné T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost. 2013;109(3):368-374.
35. Schmaier AH, Gustafson E, Idell S, Colman RW. Plasma prekallikrein assay: reversible inhibition of C-1 inhibitor by chloroform and its use in measuring prekallikrein in different mammalian species. J Lab Clin Med. 1984;104(6):882-892.
36. España F, Ratnoff OD. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents. J Lab Clin Med. 1983;102(4):487-499.
37. Werle E. Discovery of the most important kallikreins and kallikrein inhibitors. In: Erdos EG, ed. Handbook of Experimental Pharmacology. Berlin: Springer Verlag; 1970:1-6.
38. Grobe N, Weir NM, Leiva O, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectometry. Am J Physiol Cell Physiol. 2013; 304(10):C945-C953.
39. Wilson PC, Lee MH, Appleton KM, et al. The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem. 2013; 288(26):18872-18884.
40. Munoz CM, Leeb-Lundberg LM. Receptormediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. J Biol Chem. 1992;267(1):303-309.
41. Crofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific COX-2 inhibitors. A report of three cases. Arthritis Rheum. 2000; 43(8):1891-1896.
42. Zhou G, Hamik A, Nayak L, et al. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest. 2012; 122(12):4727-4731.
43. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369-2380.
44. Hamik A, Lin Z, Kumar A, et al. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007;282(18):13769-13779.
45. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation. 2000;101(18): 2144-2148.
46. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105(1):192-198.